ClinicalKey
1mo agoNews
From the article
Ivonescimab plus chemotherapy versus tislelizumab plus chemotherapy in advanced squamous non-small-cell #LungCancer (HARMONi-6): interim overall survival analysis of a randomised, double-blind, phase 3 trial in China. www.clinicalkey.com#!/content/jo...
Continue reading on clinicalkey.comYou might also wanna read
Cancer therapies in 2026: a new era of hope
مجلة المجلة | مجلة العرب الدولية·1d ago
PD-L1 High Advanced NSCLC: Is Immunotherapy Alone Always Enough?
OncoDaily·4h ago
New drug for cancer patients with ‘limited’ treatment options enters clinical trial
The Independent·2d ago
Pancreatic cancer drug daraxonrasib nearly doubles median survival in clinical trials
Scientists gave a standing ovation at a Chicago conference for clinical trial results of daraxonrasib, a pancreatic cancer drug developed by
economist.com·5d agoGSK’s Pazopanib significantly delayed tumor progression in patients with advanced kidney cancer
GSK·17y ago
GlaxoSmithKline submits European marketing authorisation application for Pazopanib in advanced kidney cancer
GSK·17y ago
Comments
Sign in to join the conversation.
No comments yet. Be the first.